Related Experiment Videos
[Aspirin and prevention of pre-eclampsia]
1Service de médecine interne, hôpital Tenon, Paris, France.
Insights
Low-dose aspirin may prevent preeclampsia and fetal growth restriction in pregnant women. Recent trials show inconsistent results due to population risk, dosage, and timing, necessitating further research into optimal use.
Area of Science:
- Obstetrics and Gynecology
- Pharmacology
- Maternal-Fetal Medicine
Context:
- Aspirin is prescribed during pregnancy to address prostanoid imbalance from placental defects and endothelial dysfunction-related thrombosis.
- While early trials consistently showed aspirin preventing preeclampsia and fetal growth retardation, recent studies have yielded conflicting results.
Purpose:
- To analyze discrepancies in aspirin's efficacy for preventing preeclampsia and fetal growth retardation.
- To explore optimal aspirin dosage, timing of introduction, and patient selection for preventing adverse pregnancy outcomes.
Summary:
- Inconsistent trial outcomes for aspirin in pregnancy may stem from variations in patient risk profiles, aspirin dosage, and treatment initiation timing.
- Evidence suggests that early aspirin treatment and achieving a measurable biological effect, potentially with higher doses, are crucial for efficacy.
- New research indicates that initiating aspirin therapy as early as the first wave of trophoblastic invasion may be beneficial, warranting further evaluation.
Impact:
- Clarifies the reasons behind conflicting research findings on aspirin's role in preventing preeclampsia and fetal growth restriction.
- Highlights the importance of early intervention and individualized treatment strategies for aspirin therapy in high-risk pregnancies.
- Suggests future research directions, including evaluating early-stage intervention, identifying predictive biomarkers, and exploring combination therapies like aspirin with heparin or antioxidants.
Abstract:
Aspirin is used in pregnant women in order to obviate the imbalance of prostanoids caused by a defective placentation, and also to counteract the widespread thrombotic tendency related to endothelial dysfunction. After a series of controlled trials which showed a very consistent effect of aspirin t prevent preeclampsia and fetal growth retardation, several recent large trials have cast the doubt, and even unbelief. Their results are analyzed in an explicative way. Discrepancies seem largely related to either studying very low-risk populations, or strong differences in aspirin dosage and/or term of introduction. In the last few years, several works have shown the critical importance of an early treatment, and also of a measurable biologic effect, which requires larger dosages than those used in the most recent trials. The doubt largely remains as for the adequate indications of this treatment. New data in the physiology of placentation suggest that it would be logical to give aspirin as early as the first wave of throphoblastic invasion. The effect of so an early treatment need to be evaluated. The search for early markers should be pursued. The combination of aspirin and heparin is under investigation. Finally, other ways of prevention, such as anti-oxidants, are also being studied.